# HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial

> **NCT07570433** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Oriol Manuel** · enrollment: 100 (estimated)

## Conditions studied

- CMV Infection

## Interventions

- **DRUG:** 50% reduction in the dose of MPA
- **DRUG:** Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus
- **DRUG:** standard antiviral therapy along with maintenance of their initial immunosuppressive therapy.

## Key facts

- **NCT ID:** NCT07570433
- **Lead sponsor:** Oriol Manuel
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-01
- **Final completion:** 2028-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570433, "HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07570433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*